Clinically validated VHH antibodies that can be readily assembled to create well differentiated next generation biotherapeutics.

Small, Stable & Robust

VHH antibodies offer advantages in the development of many highly efficacious and fast growing new biotherapeutic drugs.

Partnerships at Isogenica

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and numerous partnered pre-clinical and discovery programs.